DAG1; dystroglycan 1 (dystrophin-associated glycoprotein 1); 156DAG; A3a; AGRNR; DAG; alpha-dystroglycan; beta-dystroglycan; dystroglycan 1; 156DAG antibody; A3a antibody; AGRNR antibody; alpha-dystroglycan antibody; beta-dystroglycan antibody; DAG antibody; dystroglycan 1 antibody; dystroglycan 1 (dystrophin-associated glycoprotein 1) antibody; DAG1 antibody

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

Goat

Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.

Supplied at 0.5 mg/ml in Tris saline, 0. 02% sodium azide, pH7.3 with 0.5% bovine serum albumin.

100ug specific antibody in 200ul (lot specific)

Aliquot and store at -20 degree C. Minimize freezing and thawing.

Manufactured in an ISO 9001:2008 Certified Laboratory.

Small volumes of anti-DAG1 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Peptide ELISA (EIA), Western Blot (WB)

Peptide ELISA: Antibody detection limit dilution 1: 128000.
Western Blot: Approx 100kDa band observed in Human Skeletal Muscle lysates (calculated MW of 97.4kDa according to NP_004384.4). Approx 80kDa band observed in Mouse and Rat Skeletal Muscle lysates (calculated MW of 96.9kDa according to NP_034147.1). The observed molecular weights correspond to the glycosylated form of alpha-dystroglycan. Recommended concentration: 0.1-0.3ug/ml.

(0.2ug/ml) staining of Human Skeletal Muscle lysate (35ug protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.

(0.1ug/ml) staining of Mouse and Rat Skeletal Muscle lysate (35ug protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.

97,441 Da

dystroglycan 1

dystroglycan

Dystroglycan

Alpha-DG; Beta-DG??[Similar Products]

DAG1_HUMAN

This gene encodes dystroglycan, a central component of dystrophin-glycoprotein complex that links the extracellular matrix and the cytoskeleton in the skeletal muscle. The encoded preproprotein undergoes O- and N-glycosylation, and proteolytic processing to generate alpha and beta subunits. Certain mutations in this gene are known to cause distinct forms of muscular dystrophy. Alternative splicing results in multiple transcript variants, all encoding the same protein. [provided by RefSeq, Nov 2015]

DAG1: a cytoskeletal protein that functions as a laminin receptor. Provides a linkage between the subsarcolemmal cytoskeleton and the extracellular matrix. May be involved in autosomal recessive muscular dystrophies. Its dramatic reduction in Duchenne muscular dystrophy leads to a loss of linkage between the sarcolemma and extracellular matrix, rendering muscle fibers more susceptible to necrosis. Dystroglycan also functions as dual receptor for agrin and laminin-2 in the Schwann cell membrane. Binds to several types of arenaviruses. Is a target for the entry of Mycobacterium leprae into peripheral nerve Schwann cells. The muscle and nonmuscle isoforms of dystroglycan differ by carbohydrate moieties but not protein sequence.

Protein type: Membrane protein, integral; Motility/polarity/chemotaxis; Cytoskeletal

Chromosomal Location of Human Ortholog: 3p21

Cellular Component: basement membrane; basolateral plasma membrane; cell-cell adherens junction; costamere; cytoplasm; cytoskeleton; cytosol; dystroglycan complex; dystrophin-associated glycoprotein complex; extracellular region; extracellular space; filopodium; focal adhesion; integral to membrane; lamellipodium; lipid raft; nucleoplasm; plasma membrane; postsynaptic membrane; sarcolemma

Molecular Function: actin binding; alpha-actinin binding; calcium ion binding; laminin-1 binding; protein binding; protein complex binding; SH2 domain binding; structural constituent of muscle; tubulin binding; vinculin binding; viral receptor activity

Biological Process: calcium-dependent cell-matrix adhesion; cytoskeletal anchoring; entry of virus into host cell; extracellular matrix organization and biogenesis; membrane protein ectodomain proteolysis; morphogenesis of an epithelial sheet; myelination in the peripheral nervous system; negative regulation of cell migration; negative regulation of MAPKKK cascade; negative regulation of protein kinase B signaling cascade; nerve maturation; NLS-bearing substrate import into nucleus; protein amino acid O-linked glycosylation; regulation of gastrulation; response to peptide hormone stimulus; shape changes of embryonic cells; virus-host interaction

Disease: Muscular Dystrophy-dystroglycanopathy (congenital With Brain And Eye Anomalies), Type A, 9; Muscular Dystrophy-dystroglycanopathy (limb-girdle), Type C, 9

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.